Novo Nordisk's Pipeline Setback Raises the Stakes Ahead of Its Midyear Report

Novo Nordisk's shares drop 8.5% after Ziltivekimab fails Phase 3 trial; investors await H1 results for pipeline strategy and guidance.

The Danish pharmaceutical giant heads into Tuesday's earnings release carrying a heavier burden than a single disappointing trial result. When Novo Nordisk reports first-half figures on August 5, investors will be looking beyond the headline numbers for signs of how the company plans to offset a significant blow to its cardiovascular ambitions.

That blow landed Friday, when shares tumbled 8.48 percent to close at EUR 40.90 after the company disclosed that Ziltivekimab, its much-anticipated anti-inflammatory drug, failed its Phase 3 ZEUS trial. The stock now sits roughly 25 percent below its January peak of EUR 54.86, a gap that underscores just how much ground the company has lost in a single year. On an annual basis, the shares are down 7.10 percent.

A Drug That Hit Its Biological Target but Missed the Clinical One

The ZEUS study enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers, all receiving monthly 15-milligram doses of Ziltivekimab. The therapy performed as designed at the molecular level—it inhibited the IL-6 signaling pathway and lowered inflammatory markers in the blood. But those biological effects did not translate into clinical benefit: the drug failed to significantly reduce major cardiovascular events such as death, heart attack, and stroke compared with placebo. Compounding the disappointment, serious infections occurred more frequently among patients taking the drug.

Novo Nordisk acquired the rights to Ziltivekimab in 2020 through its $725 million takeover of Corvidia, betting that the antibody could anchor a new franchise in cardiovascular care. That bet has now soured, at least for the near term. The company said it will take a non-cash impairment charge in the third quarter, though it reaffirmed its guidance for the current fiscal year.

Two related trials remain ongoing—HERMES, studying the drug in heart failure patients, and ARTEMIS, examining its use after acute heart attacks. But results from both are not expected until the first half of 2027, leaving a long wait for any potential redemption. BMO's analyst described positive data from these follow-up studies as "highly unlikely" following the ZEUS setback, while JPMorgan analysts framed the failure as billions in lost revenue potential for the cardiometabolic segment.

Wall Street Splits on the Severity of the Blow

The analyst community has offered a notably divided read on what Friday's decline means. UBS's Matthew Weston struck a cautious tone, noting that his firm had previously modeled Ziltivekimab peak sales of around $3 billion—roughly 60 percent of what some had expected—and that the drug represented only 1.7 percent of Novo Nordisk's net present value. Even so, Weston anticipates a market reaction two to three times larger than the pure valuation impact would justify, arguing the setback intensifies pressure on the broader research pipeline.

Mizuho's Jared Holz echoed that sentiment, calling the early data disappointing and warning that it could weigh on sentiment around Novo's entire pipeline beyond its weight-loss drugs.

Others view the sell-off as overdone. Of the 26 analysts covering the stock, 18 currently recommend "Hold," and the average price target implies upside of 4.45 percent from pre-decline levels. Their reasoning: Ziltivekimab was always a modest piece of the portfolio. The strategic weight of the failure, however, is harder to dismiss—it weakens the company's diversification beyond its GLP-1 franchise and highlights just how dependent Novo Nordisk remains on Ozempic and Wegovy.

A Stock Caught Between Support Levels and Skepticism

The technical picture reflects a market that has absorbed the news without capitulating. The shares hover just above their 50-day moving average of EUR 40.90 and remain marginally above the 200-day line. The 14-day relative strength index sits at 41.8, indicating a neutral-to-slightly-oversold condition rather than panic. During a turbulent trading week, the stock swung between EUR 42.80 and EUR 45.485 before Friday's drop.

Institutional positioning tells a mixed story. Several firms added to their stakes during the first quarter, but Lazard Asset Management cut its position by roughly 89 percent. Institutions collectively hold about a tenth of the company's shares.

Retail investors are similarly torn, with some viewing the depressed valuation as a buying opportunity while others warn of a structurally weakened pipeline. The debate may well be settled—at least partially—by Tuesday's report.

What Tuesday's Numbers Will Reveal

The consensus estimate for first-half earnings per share stands at $0.81, a 16.5 percent decline from the prior-year period. First Group Bank has trimmed its full-year forecast to $3.20 per share, below the broader analyst consensus of $3.38. In the first quarter, Novo Nordisk reported EPS of $1.03 on revenue of $10.85 billion.

The earnings call will offer the first detailed look at how competitive pressures from Eli Lilly are reshaping the GLP-1 market, how the rollout of the Wegovy tablet is progressing, and whether pricing dynamics in weight-loss drugs are eroding margins. The company raised its annual guidance in May after better-than-expected first-quarter Wegovy sales, a rare bright spot in a year that followed a roughly 40 percent decline in the stock.

Legal Clouds and Strategic Questions

Investors also have a legal matter to track. A US class-action lawsuit accuses Novo Nordisk of misleading shareholders about the CagriSema study, and a federal judge recently ruled that portions of the case can proceed. The court found investors had plausibly argued that statements about tolerability and study design may have been misleading—though that is not a ruling on actual securities fraud. A company spokesperson has rejected the allegations and pledged a vigorous defense.

The Ziltivekimab failure also sharpens questions about Novo Nordisk's growth strategy beyond diabetes and obesity. Analysts see mounting pressure on management to pursue acquisitions or partnerships that could open new therapeutic avenues. One potential bright spot: oral semaglutide, which in a Phase IIIa trial reduced HbA1c levels by 0.83 percentage points versus placebo in adolescents with type 2 diabetes. The company plans to file for regulatory approval in the US and EU in the second half of the year.

For now, the immediate focus is Tuesday. The stock sits almost exactly on its 50-day average, and the earnings report will determine whether that level holds or gives way. The failed trial has already exacted a toll; the question is whether the numbers can restore some confidence.